Discover 229 paid clinical trials in Sioux Falls, South Dakota. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 229
Active & Responsive
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
for
Non-small Cell Lung Cancer (NSCLC)
1 location in Sioux Falls
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06305754
Phase3, Recruiting
Active & Responsive
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
for
Carcinoma, Non-Small-Cell Lung
1 location in Sioux Falls
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT04165798
Recruiting
Active & ResponsiveNew
Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)
for
Overactive Bladder (OAB)
1 location in Sioux Falls
Sponsor: FemPulse Corporation
Sex: Female
Age: 21+
Code: NCT07195656
Recruiting
Active & Responsive
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
for
Rare Disorders, Undiagnosed Disorders,
1 location in Sioux Falls
Sponsor: Sanford Health
Sex: All
Age: 0+
Code: NCT01793168
Recruiting
Active & Responsive
Helix Research Network
for
Genetic Predisposition to Disease, Genetics Disease
1 location in Sioux Falls
Sponsor: Helix, Inc
Sex: All
Age: 18+
Code: NCT06057181
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
for
PIK3CA Mutation, HER2- Negative Breast Cancer,
1 location in Sioux Falls
Sponsor: Relay Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT06982521
Phase3, Recruiting
Active & Responsive
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
for
Endometrial Cancer
1 location in Sioux Falls
Sponsor: Faeth Therapeutics
Sex: Female
Age: 18+
Code: NCT06463028
Phase2, Recruiting
Active & Responsive
Evaluating Patient Reported Outcomes and Surgeon Satisfaction With Ziplyft™